최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0945168 (2015-11-18) |
등록번호 | US-9655850 (2017-05-23) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 1 인용 특허 : 875 |
Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromo
Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.
1. A method for making a dry powder comprising an active agent, said method comprising: dissolving said active agent in a solution or a suspension comprising a diketopiperazine, and spray drying said solution or suspension to form a dry powder; wherein said diketopiperazine is a substituted diketopi
1. A method for making a dry powder comprising an active agent, said method comprising: dissolving said active agent in a solution or a suspension comprising a diketopiperazine, and spray drying said solution or suspension to form a dry powder; wherein said diketopiperazine is a substituted diketopiperazine or a the pharmaceutically acceptable salt of said substituted diketopiperazine having the general structure of Formula A: wherein R is an alkyl group of 1 to 10 carbons or hydrogen; X is an amide bond, an ester, a sulfone, a sulfoxide, an amine, or a ketone; and n or m represents an integer from 0 to 20, and Y is an amide, acid, hydroxyl, phenol, phosphonic acid, or thiol. 2. The method of claim 1 wherein R is hydrogen, n =3, m is C═C, X is —NHC(O)—, and Y is COOH. 3. The method of claim 1 wherein R is hydrogen, n =2, m is C═C, X is —NHC(O)—, and Y is COOH. 4. The method of claim 1 wherein R is an isopropyl, n =3, m is C═C, X is —NHC(O)—, and Y is COOH. 5. The method of claim 1 wherein the active agent is a peptide, protein, polypeptide, small molecule, or nucleic acid molecule. 6. The method of claim 5, wherein the active agent is selected from the group consisting of insulin, glucagon, glucagon like peptide 1 (GLP-1), calcitonin, parathyroid hormone 1-34, bioactive fragment of parathyroid hormone, octreotide, leuprolide, and RSV peptide, granulocyte colony stimulating factor (GM-CSF), peptide YY, oxyntomodulin, felbamate, cannabinoid antagonists and/or agonists, muscurinic antagonsits and/or agonistics, heparin, low molecular weight heparin, cromolyn, sildenafil, vardenafil, tadalafil, growth hormone, AZT, DDI, lamotrigine, chorionic gonadotropin releasing factor, luteinizing release hormone, β-galactosidase, exendins 1-4, ghrelin, tryptin, and analogs and fragments thereof. 7. The method of claim 5, wherein the active agent is insulin or an insulin analog. 8. The method of claim 7 wherein the active agent is insulin. 9. The method of claim 8 wherein the insulin is human insulin. 10. The method of claim 5, wherein the active agent is GLP-1 or a GLP-1 analog. 11. The method of claim 5, wherein the active agent is oxyntomodulin. 12. A dry powder of claim 1 for delivery to the pulmonary system. 13. The method of claim 5, wherein the active agent is parathyroid hormone 1-34 or a bioactive fragment thereof. 14. The method of claim 5 wherein the active agent is granulocyte colony stimulating factor. 15. The method of claim 5, wherein the active agent is vardenafil. 16. The method of claim 5, wherein the active agent is a cannabinoid antagonist. 17. The method of claim 5, wherein the active agent is a cannabinoid agonist. 18. The method of claim 5, wherein the active agent is sildenafil.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.